Abstract: A method for treating alcoholism by extinguishing the alcohol-drinking response in which an opiate antagonist is transdermally administered to a subject and a device for transdermally administering the antagonist. The device is a package containing a fixed dose of opiate antagonist, a vehicle and a permeation enhancer.

Abstract: A method for treating alcoholism. The alcohol-drinking response of alcoholics is extinguished by having them drink alcoholic beverages while nalmefene, an opiate antagonist, blocks the positive reinforcement effect of ethanol in the brain.

Abstract: Alcohol-related disorders are treated by the administration of adenosine antagonists and adenosine agonists to a host. Adenosine antagonists are used to inhibit both acute intoxication and chronic dependence by administering prior to alcohol consumption. The symptoms associated with alcohol withdrawal syndrome may be treated by administering adenosine agonists which reduce the physiological dependence on alcohol during the withdrawal period.

Abstract: Methods and compositions are provided for treating drug-dependent individuals so as to effect withdrawal from the drug of abuse, e.g., natural and synthetic narcotics, or stimulant-type drugs such as cocaine, amphetamines, nicotine, or the like. The method involves substitution therapy wherein a serotonin antagonist such as ergotamine or a derivative thereof and a CNS stimulant such as caffeine are substituted for the drug of abuse.

Abstract: An opiate antagonist or a pharmaceutically acceptable salt thereof is used to treat emotional numbness associated with Post Traumatic Stress Disorder and other psychopathologic conditions.

Abstract: Prevention of or therapeutically curing the disease of alcoholism comprises supplementing the diet with biologically available chromium, such as naturally occurring chelated chromium. A food bar containing chromium picolinate is also disclosed.

Abstract: The present invention provides 3,4-diphenylbutanamines capable of selectively inhibiting the uptake of serotonin and norepinephrine.

Abstract: A composition, comprising L-alanine or a salt thereof, L-glutamine or a salt thereof, and an oligopeptide containing either a L-alanine residue or a L-glutamine residue, or both, is disclosed. A composition made up of (i) L-alanine or a salt thereof, (ii) L-glutamine or a salt thereof, and (iii) an oligopeptide containing a L-alanine or a L-glutamine residue is also discloed. The L-alanine and the L-glutamine are present in these compositions in an available molar ratio of from 1:0.1 to 1:10, respectively. These compositions are useful in the therapy or prevention of hepatic disorders.

Abstract: The use of gamma-hydroxybutyric acid salts for preparing pharmaceutical compositions useful for the release form ethyl alcohol consumption and the compostions obtained.

Abstract: A method is provided for attenuating the intoxicating effects of ethyl alcohol in a patient, by administering to a patient in need thereof, an alpha-2 adrenoceptor antagonist compound. Two preferred compounds useful in the present invention, each being a highly potent and selective alpha-2 adrenoceptor antagonist, are atipamezole and idazoxan.

Abstract: The present invention provides 3-aryloxy-3-substituted propanamines capable of inhibiting the uptake of serotonin and norepinephrine.

Abstract: Medicaments for treatment of alcoholic toxicomania comprise at least one extract of vegetable origin, particularly those obtained by maceration, decoction and/or infusion in an aqueous alcoholic solvent of Capsicum peppers and/or bark or wood of Populus poplars. Preferably, the medicaments comprise mixtures containing 80% of extracts of Capsicum pepper and 20% of Populus extract formed by a mixture of small molecular weight molecules among which the predominant species exhibits a specific maximum absorption spectrum of 280 nm.

Abstract: Preventives or remedies for medicinal and alcoholic poisoning contain as a pharmaceutically effective component phytic acid or its salt which may be an innoxious metal salt, or an innoxious salt with an organic base, a basic amino acid or an organic ester residue.

Abstract: Prevention of or therapeutically curing the disease of alcoholism comprises supplementing the diet with biologically available chromium, such as naturally occurring chelated chromium.

Abstract: A pharmaceutical preparation containing a carrier with palmitoyl-fructose-1,6- diphosphate as the active drug, for use in the therapy of hypophosphatemias, of cardiopathies, and of alcoholism and relevant methods for producing said preparation.

Abstract: A therapeutic method is provided for use as an adjunct in the treatment of alcoholism. The method consists of extinguishing the alcohol-drinking response of alcoholics during a relatively short period of time by having them drink alcoholic beverage repeatedly while an opiate antagonist blocks the positive reinforcement effects of ethanol in the brain.

Abstract: Use of a physiologically inert hydrophobic molecular sieve material to lower the blood alcohol level in the human body in the form of an edible composition or a suppository, the material having a pore size permitting the absorption of ethanol but preventing the absorption of larger molecules with lipophilic character. The material may be a crystalline zeolitic material such as Silicalite or ZSM5.

Abstract: The present invention relates to the manufacture of liqueur and vodka.An alcoholic beverage comprises a composition involving 219-270 mg/g of leukoanthocyans, 153-187 mg/g of catechins, 81-99 mg/g of flavanols, 68-83 mg/g of lignin, 216-264 mg/g of reducing sugars, 18-22 mg/g of pectin, 27-33 mg/g of free aminoacids, 36-44 mg/g of organic acids, 4.5-5.5 mg/g of sterols, 1.35-1.65 mg/g of methylsterols, 1.98-2.42 mg/g of dimethylsterols, 13.5-16.5 mg/g of lignanes, 9-11 mg/g of lignane glycosides, 13.5-16.5 mg/g of phenoloacids, 4.5-5.5 mg/g of phenol aldehydes, 4.5-5.5 mg/g of alkylferulates, a fruit alcohol, sugar, citric acid, a tint and an aqueo-alcoholic liquid.The alcoholic beverage is produced by blending ingredients thereof, a triple successive heat treatment, cooling, settling and filtration.

Abstract: The present invention provides 1-phenyl-(naphthalenyl)alkylamines which are selective inhibitors of serotonin uptake.

Abstract: Acylated cyanamide compounds useful for ethanol deterrence of the formula RCONHCN, wherein R is a lipophilic acyl group or is derived from an (N-substituted)-alpha-aminoacyl group.

Abstract: The present invention relates to the therapeutical use of a pharmaceutical composition of fructose 1,6-diphosphate (FDP) (sodium salt) which, intravenously administered, treats somatic and psychic manifestations caused by alcoholic intoxication.

Abstract: Human growth hormone is used for the treatment of individuals who are intoxicated with poisonous substances of the type which is degraded in the liver by microsomal enzymes, such as hexobarbiturates or alcohol.

Abstract: The present invention relates to compositions inhibiting the development of a pathological addiction to alcohol. The composition according to the present invention consists of the following ingredients, mg/kg:______________________________________ leukoanthocyanes 219-270 catechins 153-187 flavonols 81-99 lignin 68-83 reducing sugars 216-264 pectin 18-22 free aminoacids 27-33 organic acids 36-44 sterols 4.5-5.5 methylsterols 1.35-1.65 dimethylsterols 1.98-2.42 lignans 13.5-16.5 lignan glycosides 9-11 phenolic acids 13.5-16.5 phenolic aldehydes 4.5-5.5 alkylferulates 4.5-5.

Abstract: Buspirone and its pharmaceutically acceptable salts are useful in the treatment of alcohol abuse.

Abstract: Acylated cyanamide compounds useful for ethanol deterrence of the formula RCONHCN, wherein R is a lipophilic acyl group or is derived from an (N-substituted)-alpha-aminoacyl group.

Abstract: This invention relates to therapeutic compositions containing betaine salts for the treatment of hangover and for the lowering of alcohol content in blood in human. Daily dose comprises oral administration of 1 to 30 g, associated with appropriate carrier. Optional ingredients are an analgesic, a buffering agent and caffeine.

Abstract: Microcapsules particularly those less than 300 microns in size are provided which are adapted for injection by conventional means to afford controlled release of the encapsulated drug material, such as a narcotic antagonist, an antibiotic or the like, over a prolonged period. The microcapsules are characterized by a solid core material of a solid, injectable drug material and a wall material engulfing the core material and composed of a polymer material such as a bioabsorbable polymer material. The microcapsules are made by providing a system containing a mixture of particles of a solid, injectable drug material and a solution of a bioabsorbable polymer material in a solvent in which the drug material is substantially insoluble. The system is treated to induce phase separation of the bioabsorbable polymer material from the solution by the addition to the system of a phase separation agent at a temperature at least as low as -30.degree. C.

Abstract: A pharmaceutical composition for preventing or alleviating the effects of acute alcoholism, in particular liver disturbances in mammals, which comprises a mixture of alanine or a pharmaceutically acceptable salt or derivative thereof capable of effectively acting as alanine in vivo or a mixture thereof, and ornithine or a pharmaceutically acceptable salt or derivative thereof capable of effectively acting as ornithine in vivo or a mixture thereof in a ratio such that the amount of ornithine present in said mixture is at least about 1/1000 the amount of alanine present, both of said ornithine and alanine being present in an amount effective to prevent or alleviate said effects.

Abstract: The invention relates to the preparation of 3-trifluoromethyl- and 2,5-dimethyl-4'-hydroxy-.alpha.-ethyl-benzhydrol. Both compounds have so far been described only as metabolites of corresponding benzhydrol derivatives containing no hydroxyl group. Neither their physico-chemical characteristics nor their manufacturing processes have been disclosed in the known publications.3-Trifluoromethyl- and 2,5-dimethyl-4'-hydroxy-.alpha.-ethyl-benzhydrol are suitable for the treatment of acute ethanolic intoxication. Accordingly, another aspect of the invention is a pharmaceutical composition containing one of these compounds as active ingredient.

Abstract: This invention relates to therapeutic compositions containing betaine salts for the treatment of hangover and for the lowering of alcohol content in blood in human. Daily dose comprises oral administration of 1 to 30 g, associated with appropriate carrier. Optional ingredients are an analgesic, a buffering agent and caffeine.

Abstract: A method for treating or aiding in the treatment of the manifestations of alcoholism or alcohol intoxication by aiding in the control of the craving for alcohol or by aiding in the control of alcohol withdrawal symptoms, or by aiding in the control of alcohol intoxication in a human which comprises internally administering to said human an effective amount of a compound having an active ingredient containing at least one bivalent negative sulfur to control said craving, symptoms, or intoxication so as to counteract the effects of alcohol.

Abstract: A therapeutic composition for reducing blood acetaldehyde level in a patient comprises methionine and a physiologically tolerable carrier. Additionally, potassium citrate and Vitamin B6 may be present in the composition.